- Select a blog category
By Elizabeth Hampson, Director, Monitor Deloitte
Last week, from 9th to 15th October 2021, it was Baby Loss Awareness Week (BLAW), which is now in its 19th year.1 The objective of BLAW is to raise awareness nationally about those who have been affected by pregnancy and experienced baby loss in the UK. This year’s theme is Wellbeing and throughout the week bereaved parents and their families and friends unite with others across the world to commemorate the lives of babies lost. In this week’s blog, our colleague Liz Hampson shares her personal experience with baby loss with the aim of increasing transparency and the support provided by employers.
By Adam Lowry, Advisory Senior Manager, Deloitte and Touche LLP
In the sixth prediction of our report The Future Unmasked, we predict that long-term value-based care (VBC) arrangements for medtech companies will differentiate products that offer protection from price erosion, create long-lasting relationships with customers, and increase market share and revenue by being a preferred product in 2025.1 A major aspect in achieving this future is to promote new payment models that use innovative contracting and value-based arrangements. This week’s blog, by Adam Lowry, an advisory senior manager specialising in value based care and population health strategy for providers and health plans, appeared first as a US Center for Health Solutions, Health Forward Blog and explores how value-based contracting could benefit stakeholders across the medtech ecosystem.
By Emily May, Research Analyst, Deloitte Centre for Health Solutions
Did you know that in 2020 more than 90,000 new digital health applications (apps) were added to app stores, more than 250 new apps on average, every day?1 Neither did I until conducting some research for a conference panel a couple of weeks ago. Digital health apps range from providing a platform for services such as virtual GP appointments and chronic disease management to consumer health apps that help people manage their own health through tracking daily steps and accessing exercise and nutrition programmes. This blog explores the current use of digital health apps, how the COVID-19 pandemic has accelerated their adoption, the ethical and regulatory considerations, and the potential of these apps to drive a preventative, digital-first healthcare future.
By Margaret Anderson, managing director, Deloitte Consulting LLP
Clinical trials take data from a small, but representative selection of subjects and generalise the findings to the wider population. However, as we have discussed in our previous blogs on the subject, Why improving inclusion and diversity in clinical trials should be a research priority and Diversity and inclusion in clinical trials – an imperative, especially in times of COVID-19, overcoming the lack of diversity in clinical trials is a medical and ethical imperative to achieve true representation of the patient population. This week’s blog, by Margaret Anderson, our Strategy & Analytics Diversity, Equity and Inclusion Leader in Deloitte Consulting, appeared first as a US Center for Health Solutions, Health Forward Blog and reflects on the stakeholder interviews our US colleagues conducted to understand how diversity could be improved in clinical trials.
By Glenn Snyder, principal, Benjamin Ninio, managing director, and Erik Kiær, managing director, Deloitte Consulting LLP
MedTech companies have a considerable role in driving the future of health, using transformative technology to enhance products and services and enabling predictive, preventative, personalised and participatory (4P) medicine, as we highlighted in the sixth prediction of our report, ‘The future unmasked, predicting the future of healthcare and life sciences in 2025’. A major aspect of achieving this future is the move to value-based models of care and funding. This week’s blog, by Glenn Snyder, our MedTech Practice leader in Deloitte Consulting, Benjamin Ninio, managing director in Monitor Deloitte, and Erik Kiær cofounder of Deloitte Launch, appeared first as a US Center for Health Solutions, Health Forward Blog and explores how medtech companies could transform to respond to this changing health ecosystem.
By Samrina Bhatti, Manager and Dr Karen Kirkham, Chief Medical Officer
It is with great pleasure, I introduce Karen Kirkham who joins us at Deloitte as a Partner in our Public Sector Health and Social Care practice and the firm’s new Chief Medical Officer(CMO). Karen has been a practising GP for over 30 years and, from 2016 to July 2021 was also the Clinical lead for the Dorset Integrated Care System, as well as a National Clinical Advisor for Systems Development and Population Health Management and Primary Care Transformation with NHSE/I. Karen will be continuing her clinical practice one-day-a-week.
By Karen Taylor, Director, and Pratik Avhad, Senior Analyst, Centre for Health Solutions
This week the Deloitte Academy hosted its latest ‘The Deloitte Quarterly Forward Look’ where I and my fellow Insight colleagues discussed what we are seeing and expect to happen over the next three months. My focus was on the public health impact of the COVID-19 pandemic, both globally and in the UK. I was supported in my preparation for this webinar by research from my senior analyst, Pratik Avhad, who has supported me in understanding the evolving story of the pandemic over the past 18 months. I thought I would use this week’s blog to share some of our latest research on infection numbers, vaccinations and the likelihood of another lockdown in the coming months.
By Pratik Avhad, Senior Analyst, and Maria João Cruz, PhD, Assistant Research Manager, Centre for Health Solutions
Since the start of the COVID-19 pandemic, more than 218 million cases and over 4.5 million COVID-related deaths have been reported worldwide, numbers that continue to grow.1 As long as the SARS-CoV-2 virus is in circulation, it will have an opportunity to mutate into potentially more infectious strains and remain an ever-moving target. Vaccines are an essential tool in the arsenal to combat this pandemic.2 To date, six vaccines have been approved for emergency or full use by at least one WHO-recognised stringent regulatory authority. All have been proven to be safe and effective at preventing severe disease, hospitalisation and COVID-related death.3 Vaccine developers are using a variety of technologies and techniques from the tried and tested to completely novel approaches. The first vaccine to receive emergency approval was a first-in-class synthetic messenger RNA (mRNA) vaccine4, making RNA a household word. Even though mRNA technology itself is not new, its clinical reality is still nascent and this blog explores its concept and considers what future uses might emerge.
By Krissie Ferris, Research Analyst, Centre for Health Solutions
This is my last week in the Deloitte Centre for Health Solutions, my home at Deloitte for almost two years. I'm not moving far though as I’m joining Deloitte’s Technology Digital Risk (TDR) Public Sector Health team, where I’ll be working with clients across the NHS and the wider healthcare industry to digitise ways of working and to help realise the huge opportunities for operational efficiencies and improved patient outcomes that can be enabled through technology. Having started my career in the NHS, I’m excited to start this new chapter and bring with me the knowledge and skills I’ve developed in my research role at the Centre. This blog reflects on my fabulous time at Deloitte so far and shares some of the reasons I’m looking forward to joining the health team.
By Emma Gould, Manager, and Scott Grainger, Manager, Deloitte Risk Advisory
When the first wave of COVID-19 hit the UK, the NHS had to prepare for worst-case scenarios. Plans for temporary hospitals and surge critical care capacity were rapidly drawn up, non-urgent services were significantly scaled down, and large numbers of staff were redeployed to ensure the NHS would be able to care for the impending rush of severely ill patients. More than a year on, and in the midst of another surge in positive cases, the true scale of the pandemic’s impact on wider health provision is starting to emerge as hospitals face an uphill battle to restore and recover elective services alongside increasing COVID-19 admissions.
By Jonathan Fox, Managing Director, Deloitte Consulting US, and Hanno Ronte, Partner, Monitor Deloitte UK
Let’s talk about trust, specifically, consumer trust in biopharmaceutical (biopharma) manufacturers. Why do consumers trust or distrust biopharma companies? What do consumers think biopharma should do to increase trust? Can companies use digital capabilities to build, or in some cases rebuild, consumer trust? Why is trust important? These were some of the questions we discussed at a digital leader’ roundtable event at LSX’s World Congress USA event which Deloitte was a sponsor. This week’s blog provides our personal take on the key takeaways to emerge from that discussion.